- 期刊
- Ahead-of-Print
淺談胃黏膜相關淋巴組織淋巴瘤治療趨勢
Trends in Treatment Strategies for Gastric Mucosa-associated Lymphoid Tissue Lymphoma
摘要
胃黏膜相關淋巴組織淋巴瘤（mucosa associated lymphoid tissue lymphoma, MALT lymphoma）為淋巴結外邊緣區淋巴瘤（Extranodal Marginal Zone Lymphoma）是一種惰性（indolent）B細胞淋巴瘤，也是常見的原發性胃淋巴瘤，大多與幽門桿菌（Helicobacter pylori, H. pylori）感染有關，不論分期皆會以根除治療（eradication therapy）做為第一線治療方式，若幽門桿菌陰性或根除治療後反應不佳，則建議應進行放射治療，對於早期胃MALT淋巴瘤病人治療效果良好，或依據疾病特性可採取「觀察及等待」策略持續評估，晚期病人能透過化學免疫治療對於疾病控制及存活率有所改善，手術不再是必要的選擇，並且建議後續接受常規內視鏡監測。
並列摘要
Extranodal marginal zone lymphoma of gastric mucosa-associated lymphoid tissue (MALT) lymphoma is a type of indolent B-cell lymphoma and the most common primary gastric lymphoma, mostly related to Helicobacter pylori infection. Eradication therapy is the first-line treatment for gastric MALT lymphoma at all stages. Radiotherapy is recommended for H. pylori-negative gastric MALT lymphoma or poor responder of eradication therapy. A watch-and-wait approach with continuous assessment may be adopted per disease characteristics for early-stage gastric MALT lymphoma patients with good treatment responses. For late-stage patients, chemoimmuno-therapy may improve disease control and survival. Surgery is no longer mandatory, and routine endoscopic surveillance is highly recommended.